Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Verträglichkeit (9 Abbildungen)
Übersicht


Zum ersten Bild Abb. 1: Verträglichkeit Abb. 2: Telmisartan - Placebo - Verträglichkeit Abb. 3: Telmisartan - Verträglichkeit Aktuelles Bild - Abb. 4: Telmisartan - HCTZ - Verträglichkeit Abb. 5: Verträglichkeitsprofil Abb. 6: Verträglichkeitsprofil Abb. 7: Verträglichkeitsprofil Zum letzten Bild
Abbildung 4: Telmisartan - HCTZ - Verträglichkeit
Safety data were collected from 34 multicentre randomized studies, the majority of which were double-blind, which recruited 6,915 patients.1 Patients received placebo, telmisartan 10–160 mg, or telmisartan 10–160 mg + HCTZ 6.25–25 mg for a minimum of 7 days and up to >2 years. 819 patients were treated with placebo, 6575 treated with telmisartan, and 2180 patients were treated with telmisartan + HCTZ. When calculated according to exposure to study drug, treatment-related adverse events were low with both telmisartan monotherapy and combination therapy. The incidence of adverse events were similar in younger (< 65 years) and elderly (≥ 65 years) patients. 1. Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54.
 
Telmisartan - HCTZ - Verträglichkeit
Vorheriges Bild Nächstes Bild   


Abbildung 4: Telmisartan - HCTZ - Verträglichkeit
Safety data were collected from 34 multicentre randomized studies, the majority of which were double-blind, which recruited 6,915 patients.1 Patients received placebo, telmisartan 10–160 mg, or telmisartan 10–160 mg + HCTZ 6.25–25 mg for a minimum of 7 days and up to >2 years. 819 patients were treated with placebo, 6575 treated with telmisartan, and 2180 patients were treated with telmisartan + HCTZ. When calculated according to exposure to study drug, treatment-related adverse events were low with both telmisartan monotherapy and combination therapy. The incidence of adverse events were similar in younger (< 65 years) and elderly (≥ 65 years) patients. 1. Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung